Sesen Bio, Inc. – NASDAQ:SESN
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Sesen Bio stock price monthly change
+4.83%
month
Sesen Bio stock price quarterly change
+18.12%
quarter
Sesen Bio stock price yearly change
+5.29%
year
Sesen Bio key metrics
Market Cap | 127.95M |
Enterprise value | 70.65M |
P/E | -0.15 |
EV/Sales | 0.84 |
EV/EBITDA | -1.40 |
Price/Sales | 1.53 |
Price/Book | 0.09 |
PEG ratio | N/A |
EPS | -4.49 |
Revenue | 50.63M |
EBITDA | -74.81M |
Income | -81.24M |
Revenue Q/Q | -90.43% |
Revenue Y/Y | -15.61% |
Profit margin | -61.83% |
Oper. margin | -61.63% |
Gross margin | 100% |
EBIT margin | -61.63% |
EBITDA margin | -147.77% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSesen Bio stock price history
Sesen Bio stock forecast
Sesen Bio financial statements
| Dec 2022 | 40M | -15.32M | -38.31% |
|---|---|---|---|
| Mar 2023 | 3.24M | -24.64M | -759.85% |
| Jun 2023 | 3.56M | -19.87M | -558.31% |
| Sep 2023 | 3.82M | -21.40M | -559.26% |
| 2022-08-08 | -3.94421 | -3.20459 |
|---|---|---|
| 2022-11-07 | -1.2904 | 2 |
| 2023-02-28 | -0.01454 | -0.04 |
| Dec 2022 | 189174000 | 30.98M | 16.38% |
|---|---|---|---|
| Mar 2023 | 156132000 | 70.06M | 44.87% |
| Jun 2023 | 133013000 | 66.30M | 49.85% |
| Sep 2023 | 106784000 | 60.48M | 56.64% |
| Jun 2022 | -8.59M | -89.09M | 0 |
|---|---|---|---|
| Sep 2022 | 23.65M | -24.63M | 0 |
| Dec 2022 | 2.68M | 59.76M | 1K |
| Mar 2023 | -25.53M | -3.59M | 67.74M |
Sesen Bio alternative data
| Aug 2023 | 17 |
|---|---|
| Sep 2023 | 17 |
| Oct 2023 | 17 |
| Nov 2023 | 17 |
| Dec 2023 | 17 |
| Jan 2024 | 17 |
| Feb 2024 | 17 |
| Mar 2024 | 17 |
| Apr 2024 | 17 |
| May 2024 | 17 |
| Jun 2024 | 17 |
| Jul 2024 | 17 |
Sesen Bio other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 0 | 188506 |
| Mar 2023 | 0 | 1240215 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | RYU ELLY officer: Principal Accounting O.. | Common Stock | 17,289 | $0.59 | $10,149 | ||
Sale | MACDONALD GLEN C officer: Chief Te.. | Common Stock | 60,237 | $0.59 | $35,359 | ||
Sale | FORBES MONICA officer: Chief Fi.. | Common Stock | 98,304 | $0.59 | $57,704 | ||
Sale | SULLIVAN MARK officer: General Counsel & Secr.. | Common Stock | 44,879 | $0.59 | $26,344 | ||
Option | SULLIVAN MARK officer: General Counsel & Secr.. | Common Stock | 113,175 | $0.59 | $66,434 | ||
Sale | SULLIVAN MARK officer: General Counsel & Secr.. | Common Stock | 73,361 | $0.59 | $43,063 | ||
Option | SULLIVAN MARK officer: General Counsel & Secr.. | Common Stock | 185,000 | $0.59 | $108,595 | ||
Sale | SULLIVAN MARK officer: General Counsel & Secr.. | Common Stock | 100,978 | $0.59 | $59,274 | ||
Sale | CANNELL THOMAS R director, officer.. | Common Stock | 278,564 | $0.59 | $163,517 | ||
Option | CANNELL THOMAS R director, officer.. | Common Stock | 606,800 | $0.59 | $356,192 |
| Quarter | Transcript |
|---|---|
| Q1 2021 10 May 2021 | Q1 2021 Earnings Call Transcript |
| Q1 2020 11 May 2020 | Q1 2020 Earnings Call Transcript |
| Q4 2019 16 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Q3 2019 12 Nov 2019 | Q3 2019 Earnings Call Transcript |
Imara: Potential Liquidation
Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies
Sesen Bio: Binary Event Approaching
Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
Sesen: Vicineum Could Be The Ultimate Catalyst
-
When is Sesen Bio's next earnings date?
Unfortunately, Sesen Bio's (SESN) next earnings date is currently unknown.
-
Does Sesen Bio pay dividends?
Yes, Sesen Bio pays dividends and its trailing 12-month yield is 57.25% with 0% payout ratio. The last Sesen Bio stock dividend of undefined was paid on 26 Sep 2025.
-
How much money does Sesen Bio make?
Sesen Bio has a market capitalization of 127.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 50.69% to 40M US dollars. Sesen Bio made a loss 19.88M US dollars in net income (profit) last year or -$0.04 on an earnings per share basis.
-
What is Sesen Bio's stock symbol?
Sesen Bio, Inc. is traded on the NASDAQ under the ticker symbol "SESN".
-
What is Sesen Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sesen Bio?
Shares of Sesen Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sesen Bio's key executives?
Sesen Bio's management team includes the following people:
- Dr. Thomas R. Cannell Pres, Chief Executive Officer & Director(age: 63, pay: $885,060)
- Ms. Monica Forbes Chief Financial Officer & Treasurer(age: 49, pay: $536,000)
- Dr. Glen C. MacDonald Chief Technology Officer(age: 74, pay: $519,700)
-
How many employees does Sesen Bio have?
As Jul 2024, Sesen Bio employs 17 workers.
-
When Sesen Bio went public?
Sesen Bio, Inc. is publicly traded company for more then 11 years since IPO on 6 Feb 2014.
-
What is Sesen Bio's official website?
The official website for Sesen Bio is sesenbio.com.
-
Where are Sesen Bio's headquarters?
Sesen Bio is headquartered at 245 First Street, Cambridge, MA.
-
How can i contact Sesen Bio?
Sesen Bio's mailing address is 245 First Street, Cambridge, MA and company can be reached via phone at +61 74448550.
Sesen Bio company profile:
Sesen Bio, Inc.
sesenbio.comExchange:
NASDAQ
Full time employees:
17
Industry:
Biotechnology
Sector:
Healthcare
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
245 First Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001485003
ISIN: US8177631053
CUSIP: 817763105
